LEADER 01641nam 2200397 450 001 000013843 005 20070503173100.0 010 $a2-7283-0116-6 100 $a20030606d1988----km-y0itay0103----ba 101 0 $afre 102 $aFR 200 1 $a<> souvenir des évêques$eSépultures, listes épiscopales et culte des évêques en Italie du Nord des origines au 10. siècle$fpar Jean-Charles Picard 200 1 $a1 $n0001303 210 $aRome$cÉcole française de Rome$d1988 215 $a819 p., [25] c. di tav.$cill.$d25 cm. 225 2 $aBibliothèque des écoles françaises d'Athènes et de Rome$v268 410 0$12001$aBibliothèque des écoles françaises d'Athènes et de Rome$v268 606 $aVescovi$yItalia settentrionale$xOrigini-Sec. 10.$xSepoltura 606 $aSanti$xCulto$yItalia settentrionale$xSec. 4.-10. 676 $a282.092$v(21. ed.)$9Chiesa cattolica romana. Persone 700 1$aPicard,$bJean Charles$0158946 801 0$aIT$bUniversità della Basilicata - B.I.A.$gRICA$2unimarc 912 $a000013843 996 $aSouvenir des évêques$91526934 997 $aUNIBAS BAS $aLETTERE CAT $aSTD022$b01$c20030606$lBAS01$h1221 CAT $aDILEO$b21$c20030916$lBAS01$h1135 CAT $c20050601$lBAS01$h1755 CAT $abatch$b01$c20050718$lBAS01$h1052 CAT $c20050718$lBAS01$h1111 CAT $c20050718$lBAS01$h1141 CAT $c20050718$lBAS01$h1155 CAT $aBATCH$b00$c20070503$lBAS01$h1731 FMT Z30 -1$lBAS01$LBAS01$mBOOK$1BASA1$APolo Storico-Umanistico$2DSLA$BCollezione DiSSLA$3DD/5184$65184$5D5184$820030606$f04$FPrestabile Didattica LEADER 04317nam 2200541 450 001 9910829938603321 005 20210209142525.0 010 $a1-118-93323-0 010 $a1-119-01504-9 010 $a1-118-93324-9 035 $a(CKB)3710000000412048 035 $a(EBL)1895151 035 $a(SSID)ssj0001499492 035 $a(PQKBManifestationID)11820094 035 $a(PQKBTitleCode)TC0001499492 035 $a(PQKBWorkID)11512861 035 $a(PQKB)11323784 035 $a(MiAaPQ)EBC4039989 035 $a(DLC) 2015014757 035 $a(MiAaPQ)EBC1895151 035 $a(EXLCZ)993710000000412048 100 $a20160215h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aSemi-organic growth + website $etactics and strategies behind Google's success /$fGeorge T. Geis 210 1$aHoboken, New Jersey :$cWiley,$d2015. 210 4$d©2015 215 $a1 online resource (243 p.) 300 $aDescription based upon print version of record. 311 $a1-118-93322-2 320 $aIncludes bibliographical references and index. 327 $aMachine generated contents note: Preface Acknowledgments Chapter 1: M&A Success and Failure Chapter 2: Imprinting Semi-organic Growth Chapter 3: Google v. Apple: M&A Paths Diverge, then Converge Chapter 4: M&A Market Modeling Chapter 5: Google Media Deals Chapter 6: Google Internet Deals Chapter 7: Google Technology Platform Deals Chapter 8: Failed or Shuttered Deals Chapter 9: Disclosure versus Secrecy Chapter 10: Forms of Consideration Chapter 11: Contingent Consideration Chapter 12: Dimensions of M&A Integration and Semi-organic Growth Chapter 13: Acqui-hires Enhancing Google Offerings Chapter 14: Competitive Deal Constellations and Ecosystem Synergy References About the Website About the Author Index . 330 $a"An in-depth examination of Google's innovative approach to M&A Semi-Organic Growth presents a unique analysis of Google's distinctive expertise in the area of mergers and acquisitions, derived from more than 150 acquisitions carried out over the company's short history. While organizational growth has traditionally been characterized as organic (internally generated) or inorganic (from acquisition), this book examines Google's semi-organic strategy for accelerating product and service revenue, explained through a unique sector/subsector classification scheme that dynamically maps the media, Internet, and technology platform markets. You'll gain insight into Google's disclosure strategies for private company transactions, and more importantly, their methods for integrating acquisitions into product and service offerings to achieve ecosystem synergy. Unique perspective reveals the lessons learned along the way from both successes and failures, and the companion website gives you access to the tools that help you implement what you've learned. Google's extensive use of M&A as a growth strategy has been in sharp contrast to the practices of rivals like Apple, and further contrasts with the failures of many other companies in corporate business development. This book shows you the thinking behind the company's successful methods, and demonstrates the mechanisms behind the success. Learn why corporate M&A activity often fails to add value Delve deep into the complex dimensions of M&A integration Discover what Google has learned through specific deals Consider innovative integration methods that foster synergy Google is an iconic, premiere company, and it didn't happen by accident. Their success is driven by their innovative approach to strategy in all areas, and their M&A expertise has been a major contributing factor. Semi-Organic Growth takes you through the core workings of Google M&A to provide insight into successful strategy for the modern market"--$cProvided by publisher. 606 $aConsolidation and merger of corporations 615 0$aConsolidation and merger of corporations. 676 $a658.4/012 686 $aBUS015000$2bisacsh 700 $aGeis$b George T.$01634209 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910829938603321 996 $aSemi-organic growth + website$93974317 997 $aUNINA LEADER 04423nam 22005535 450 001 9910349444703321 005 20200701071335.0 010 $a3-030-00054-0 024 7 $a10.1007/978-3-030-00054-7 035 $a(CKB)4100000009191094 035 $a(DE-He213)978-3-030-00054-7 035 $a(MiAaPQ)EBC5894523 035 $a(PPN)257359303 035 $a(EXLCZ)994100000009191094 100 $a20190909d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aChagas Disease $eA Clinical Approach /$fedited by Jaime Marcelo Altcheh, Hector Freilij 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (XII, 356 p. 48 illus., 34 illus. in color.) 225 1 $aBirkhäuser Advances in Infectious Diseases,$x2504-3811 311 $a3-030-00053-2 327 $aOverview -- Chapter 1: Chagas disease: past, present and future -- The agent -- Chapter 2: Trypanosoma cruzi Journey from the Insect Vector to the Host Cell -- Chapter 3: A panoramic view of the immune response to Trypanosoma cruzi infection -- Epidemiology -- Chapter 4: Epidemiology of Chagas Disease -- Chapter 5: Chagas Disease in Europe -- Chapter 6: Chagas Disease in the United States (USA) -- Diagnosis -- Chapter 7: Diagnosis of Chagas disease -- Clinical aspects -- Chapter 8: Acute vector-borne Chagas disease -- Chapter 9: Congenital Chagas Disease -- Chapter 10: Chronic Trypanosoma cruzi Infection: Decision Making in the Midst of Uncertainty -- Chapter 11: Orally-Transmitted Chagas Disease: a Neglected Foodborne Infection -- Chapter 12: Gastrointestinal Chagas Disease -- Chapter 13: Chagas in immunosuppressed patients -- Treatment -- Chapter 14: CLINICAL PHARMACOLOGY OF DRUGS FOR THE TREATMENT OF CHAGAS DISEASE -- Chapter 15: In vivo Drug Testing for Experimental Trypanosoma cruzi Infection -- Chapter 16: Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities. 330 $aChagas disease is a potentially life threatening condition that was historically mainly endemic to Latin America. Over the last decade, however, the disease has spread to and is increasingly prevalent in other continents such as North America and Europe, with an estimated 7 million people infected worldwide. It is primarily transmitted by insect vectors that carry the parasite Trypanosoma cruzi, the disease agent. In areas where there is vector control and in non-endemic countries, it is mainly transmitted via congenital infection. Cardiac and gastrointestinal complications are common in untreated individuals.This book offers a comprehensive overview of Chagas disease, including its vectorial and congenital transmission, and molecular diagnosis, which is essential for screening, and developing and providing timely, effective anti-trypanosomal treatment. Written by experts working with infected patients on a daily basis, it discusses the pathogenesis of congenital, cardiac, gastrointestinal and oral Chagas disease, as well as its treatment and the pharmacological aspects of drug development in this area. The chapter, ?Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities? is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com. 410 0$aBirkhäuser Advances in Infectious Diseases,$x2504-3811 606 $aMolecular biology 606 $aParasitology 606 $aInfectious diseases 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aParasitology$3https://scigraph.springernature.com/ontologies/product-market-codes/B19002 606 $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096 615 0$aMolecular biology. 615 0$aParasitology. 615 0$aInfectious diseases. 615 14$aMolecular Medicine. 615 24$aParasitology. 615 24$aInfectious Diseases. 676 $a611.01816 676 $a616.9363 702 $aAltcheh$b Jaime Marcelo$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFreilij$b Hector$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910349444703321 996 $aChagas Disease$91994004 997 $aUNINA